Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2012 Financial Results
Date:3/11/2013

in research and development expenses related to the Zerenex clinical program.  The net loss for the fourth quarter ended December 31, 2012, included $0.5 million of non-cash compensation expense related to equity incentive grants.

The net loss for the year ended December 31, 2012, was $22.7 million, or $0.32 per share, compared to a net loss of $28.1 million, or $0.42 per share, for the year ended December 31, 2011, representing a decrease in net loss of $5.4 million.  The change in net loss in the year ended December 31, 2012, as compared to 2011, was primarily attributable to an $8.9 million decrease in research and development expenses due to the cessation of the development of KRX-0401 (perifosine) in May 2012, partially offset by a $2.5 million increase in research and development expenses related to the Zerenex clinical program.  The net loss for the year ended December 31, 2011, included license revenue of $5.0 million related to a milestone payment from JT and Torii for their commencement, in April 2011, of a Phase 3 clinical program in Japan.  The net loss for the year ended December 31, 2012, included a non-cash extraordinary gain of $2.6 million related to a write-off of the contingent equity rights liability following the termination of the license agreement for KRX-0401 in May 2012 and $2.2 million of non-cash compensation expense related to equity incentive grants. 

Ron Bentsur , the Company's Chief Executive Officer, commented, "In January, we reached a major milestone with the announcement of successful top-line results from the long-term Phase 3 study of Zerenex.  Following that announcement, we solidified our balance sheet with a substantial capital raise, allowing us to focus on the next key milestones for the Company, specifically, our pending U.S. New Drug Application and European Marketing Authorization Application filings and a potential launch for Zerenex in the middl
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. To Host Conference Call on Fourth Quarter and Year-End 2012 Financial Results
2. Keryx Biopharmaceuticals to Present at the Citigroup 2013 Global Healthcare Conference
3. Keryx Biopharmaceuticals Announces Pricing of Public Offering of Common Stock
4. Keryx Biopharmaceuticals Announces $55 Million Proposed Public Offering of Common Stock
5. Keryx Biopharmaceuticals, Inc. To Host Conference Call on Third Quarter 2012 Financial Results
6. Keryx Biopharmaceuticals, Inc. To Host Conference Call on Second Quarter 2012 Financial Results
7. Keryx Biopharmaceuticals Announces Upcoming Poster Presentation of Zerenex™ (ferric citrate) at the 49th ERA-EDTA Congress
8. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
9. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
10. Par Pharmaceutical Announces Quarterly Conference Call
11. HeartWare International, Inc. Announces Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... , Aug. 31, 2015 Research and ... of the "Prescription Pain Drugs - Including ... - Global Markets, Competitors and Opportunities: 2015 - ... offering. Pain is defined as ... actual or potential tissue damage. At some point, ...
(Date:8/29/2015)... 29, 2015 La sofisticada ... los sistemas de imagen por Ultrasonidos   ofrece resultados ... examen rápidos y un flujo de trabajo   optimizado, ... el proceso de detección de Cardiopatías   ... hoy el lanzamiento europeo de HeartModel A.I ...
(Date:8/28/2015)... SOUTH SAN FRANCISCO, Calif. , Aug. 28, 2015 ... therapeutics for the treatment of cancer, today announced the ... the U.S. Securities and Exchange Commission (SEC) relating to ... The number of shares to be offered and the ... determined. CytomX intends to list its common stock under ...
Breaking Medicine Technology:Prescription Pain Drugs Including Opioid, Anticonvulsant, Injectable/ Inhaled, Topical/ Transdermal, Medical Marijuana - 2015-2020 Analysis and Forecasts 2Prescription Pain Drugs Including Opioid, Anticonvulsant, Injectable/ Inhaled, Topical/ Transdermal, Medical Marijuana - 2015-2020 Analysis and Forecasts 3Philips presenta HeartModel A.I en el Congreso ESC 2015 2Philips presenta HeartModel A.I en el Congreso ESC 2015 3Philips presenta HeartModel A.I en el Congreso ESC 2015 4Philips presenta HeartModel A.I en el Congreso ESC 2015 5CytomX Files Registration Statement for Proposed Initial Public Offering 2
(Date:8/31/2015)... ... August 31, 2015 , ... ... was formed in 2008, the result of a merger of five of the ... working cooperatively, they could provide more cost-effective and higher quality care than they ...
(Date:8/31/2015)... Scotch Plains, NJ (PRWEB) , ... August 31, 2015 , ... NJ Top Docs Presents, ... Doc”!, Born and raised in Park Ridge, New Jersey, Dr. Michael Betsy graduated from Don ... and ice hockey and served as team captain in both sports in his senior year. ...
(Date:8/31/2015)... ... , ... Dr. Stewart Shofner of Shofner Vision Center explains what ... a comprehensive eye examination can diagnose amblyopia. According to the National Eye Institute ... approximately 2 to 3 out of every 100 children. , Dr. Shofner adds, ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... communications company announced today that it has officially launched a new website and ... website and brand refresh are more closely aligned with the company’s strategic vision ...
(Date:8/31/2015)... ... ... Three Bakers Gluten Free Bakery launched the redesign of its website, ... on their offering of gluten-free breads and pizzas, living without gluten, and resources for ... to share information about our gluten free product offerings, but also to really be ...
Breaking Medicine News(10 mins):Health News:NJ Top Docs Presents, Garden State Urology! 2Health News:NJ Top Docs Presents, Dr. Michael Betsy! 2Health News:NJ Top Docs Presents, Dr. Michael Betsy! 3Health News:Renowned Eye Surgeon Dr. Stewart Shofner Shares Information about the Causes of Lazy Eye During Amblyopia Awareness Month 2Health News:Renowned Eye Surgeon Dr. Stewart Shofner Shares Information about the Causes of Lazy Eye During Amblyopia Awareness Month 3Health News:Diablo Publications Launches New Company Website 2Health News:Diablo Publications Launches New Company Website 3Health News:Three Bakers Gluten Free Bakery Announces Launch of New Website 2
... Locoid Lotion was recently introduced at the ... Chicago, Illinois, for the treatment of mild-to-moderate ... Triax Pharmaceuticals, LLC, the marketers of Locoid ... brand in corticosteroids, recently launched the new ...
... 12, 2008 (Portland, Ore.) People who lose weight ... control of their blood pressure and blood sugar, and are ... their weight, according to a Kaiser Permanente study published online ... , This is the first clinical study to ...
... to the Head of the Class, WASHINGTON, Aug. ... heading back to classrooms this month, and 8,million (16%) ... according to the Asthma and Allergy Foundation of America,s,(AAFA) ... Asthma and,Allergy Policies for Schools -- many schools are ...
... MEDRAD, INC., announced today,that the wireless version ... Food and Drug Administration (FDA) 510(k) clearance., ... Continuum Wireless MR Infusion System enables the clinician ... resonance (MR),procedure from both inside and outside the ...
... ETHEX Corporation Subsidiary ... of October 24, 2008 for Gestiva(TM), ST. LOUIS, Aug. 11 KV Pharmaceutical Company,(NYSE: KVa/KVb) ... Fiscal 2009 First Quarter Financial Highlights (Unaudited), USD in millions ... Change ...
... Celsius Holdings,Inc. (OTC Bulletin Board: CSUH.OB) reported net sales ... $1.0 million -- a substantial increase,as compared to $376,000 for ... reported a net loss of $916,000 (or $0.01 per basic ... This compares,with net loss of $726,000 (or $0.01 per basic ...
Cached Medicine News:Health News:Triax Pharmaceuticals Launches New Mid-Potency Corticosteroid Vehicle, Locoid Lotion 0.1% 2Health News:Triax Pharmaceuticals Launches New Mid-Potency Corticosteroid Vehicle, Locoid Lotion 0.1% 3Health News:Triax Pharmaceuticals Launches New Mid-Potency Corticosteroid Vehicle, Locoid Lotion 0.1% 4Health News:Losing weight soon after type 2 diabetes diagnosis doubles positive outcomes 2Health News:Six States Named to National Asthma & Allergy Honor Roll 2Health News:Six States Named to National Asthma & Allergy Honor Roll 3Health News:MEDRAD Receives FDA 510(k) Clearance for Wireless MR Infusion System 2Health News:MEDRAD Receives FDA 510(k) Clearance for Wireless MR Infusion System 3Health News:KV Pharmaceutical Company Reports Fiscal 2009 First Quarter Results 2Health News:KV Pharmaceutical Company Reports Fiscal 2009 First Quarter Results 3Health News:KV Pharmaceutical Company Reports Fiscal 2009 First Quarter Results 4Health News:KV Pharmaceutical Company Reports Fiscal 2009 First Quarter Results 5Health News:KV Pharmaceutical Company Reports Fiscal 2009 First Quarter Results 6Health News:KV Pharmaceutical Company Reports Fiscal 2009 First Quarter Results 7Health News:KV Pharmaceutical Company Reports Fiscal 2009 First Quarter Results 8Health News:KV Pharmaceutical Company Reports Fiscal 2009 First Quarter Results 9Health News:KV Pharmaceutical Company Reports Fiscal 2009 First Quarter Results 10Health News:KV Pharmaceutical Company Reports Fiscal 2009 First Quarter Results 11Health News:KV Pharmaceutical Company Reports Fiscal 2009 First Quarter Results 12Health News:KV Pharmaceutical Company Reports Fiscal 2009 First Quarter Results 13Health News:KV Pharmaceutical Company Reports Fiscal 2009 First Quarter Results 14Health News:Celsius Holdings Reports Increased Revenue 2nd Quarter Revenue Increased 166% 2Health News:Celsius Holdings Reports Increased Revenue 2nd Quarter Revenue Increased 166% 3Health News:Celsius Holdings Reports Increased Revenue 2nd Quarter Revenue Increased 166% 4Health News:Celsius Holdings Reports Increased Revenue 2nd Quarter Revenue Increased 166% 5
The Plasma Extractor is used to express blood components from collection containers. The spring-loaded front panel exerts pressure on the collection container causing the fluid to transfer until cont...
The Eppendorf Maxipettor is a continuously adjustable pipette for precise pipetting of volumes up to 10 ml (in 10 l increments). Even liquids with a high vapor pressure or viscosity can be pipetted w...
... only catheter of its kind, the ... collects real-time cardiac electrical information, translating ... With 64 electrodes, this unique tool ... than 3,000 points of electrical data ...
... The St. Jude Medical® Pacing System Analyzer ... solution for implantation testing, programming and interrogation ... as an easy-to-use accessory to the St. ... testing by obtaining measurements of intrinsic P- ...
Medicine Products: